122 related articles for article (PubMed ID: 25446566)
21. Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial.
Maleki-Yazdi MR; Kaelin T; Richard N; Zvarich M; Church A
Respir Med; 2014 Dec; 108(12):1752-60. PubMed ID: 25458157
[TBL] [Abstract][Full Text] [Related]
22. Comparative effectiveness of budesonide/formoterol combination and tiotropium bromide among COPD patients new to these controller treatments.
Trudo F; Kern DM; Davis JR; Tunceli O; Zhou S; Graham EL; Strange C; Williams SA
Int J Chron Obstruct Pulmon Dis; 2015; 10():2055-66. PubMed ID: 26451101
[TBL] [Abstract][Full Text] [Related]
23. Dual bronchodilator therapy with aclidinium bromide/formoterol fumarate for chronic obstructive pulmonary disease.
D'Urzo T; Donohue JF; Price D; Miravitlles M; Kerwin E
Expert Rev Respir Med; 2015 Oct; 9(5):519-32. PubMed ID: 26366803
[TBL] [Abstract][Full Text] [Related]
24. The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease.
Beeh KM; Westerman J; Kirsten AM; Hébert J; Grönke L; Hamilton A; Tetzlaff K; Derom E
Pulm Pharmacol Ther; 2015 Jun; 32():53-9. PubMed ID: 25956072
[TBL] [Abstract][Full Text] [Related]
25. One-Year Safety of Olodaterol Once Daily via Respimat® in Patients with GOLD 2-4 Chronic Obstructive Pulmonary Disease: Results of a Pre-Specified Pooled Analysis.
McGarvey L; Niewoehner D; Magder S; Sachs P; Tetzlaff K; Hamilton A; Korducki L; Bothner U; Vogelmeier C; Koch A; Ferguson GT
COPD; 2015; 12(5):484-93. PubMed ID: 25692310
[TBL] [Abstract][Full Text] [Related]
26. Profile of inhaled glycopyrronium bromide as monotherapy and in fixed-dose combination with indacaterol maleate for the treatment of COPD.
Prakash A; Babu KS; Morjaria JB
Int J Chron Obstruct Pulmon Dis; 2015; 10():111-23. PubMed ID: 25609944
[TBL] [Abstract][Full Text] [Related]
27. A Systematic Review of the Efficacy and Safety of a Fixed-Dose Combination of Umeclidinium and Vilanterol for the Treatment of COPD.
Rodrigo GJ; Neffen H
Chest; 2015 Aug; 148(2):397-407. PubMed ID: 25798635
[TBL] [Abstract][Full Text] [Related]
28. Pharmacologic rationale, efficacy and safety of the fixed-dose co-formulation of indacaterol and glycopyrronium.
Pelaia G; Maselli R; Gallelli L
Multidiscip Respir Med; 2014; 9(1):64. PubMed ID: 25699181
[TBL] [Abstract][Full Text] [Related]
29. Umeclidinium/vilanterol combination inhaler efficacy and potential impact on current chronic obstructive pulmonary disease management guidelines.
Davidson JF; Donohue JF; Ohar JA
Expert Opin Drug Saf; 2015 Feb; 14(2):317-24. PubMed ID: 25598422
[TBL] [Abstract][Full Text] [Related]
30. CHF6001 I: a novel highly potent and selective phosphodiesterase 4 inhibitor with robust anti-inflammatory activity and suitable for topical pulmonary administration.
Moretto N; Caruso P; Bosco R; Marchini G; Pastore F; Armani E; Amari G; Rizzi A; Ghidini E; De Fanti R; Capaldi C; Carzaniga L; Hirsch E; Buccellati C; Sala A; Carnini C; Patacchini R; Delcanale M; Civelli M; Villetti G; Facchinetti F
J Pharmacol Exp Ther; 2015 Mar; 352(3):559-67. PubMed ID: 25576075
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of fluticasone propionate/formoterol fumarate in the treatment of asthma: a pooled analysis.
Papi A; Price D; Sastre J; Kaiser K; Lomax M; McIver T; Dissanayake S
Respir Med; 2015 Feb; 109(2):208-17. PubMed ID: 25575940
[TBL] [Abstract][Full Text] [Related]
32. The use of β2-agonist therapy before hospital attendance for severe asthma exacerbations: a post-hoc analysis.
Patel M; Pilcher J; Hancox RJ; Sheahan D; Pritchard A; Braithwaite I; Shaw D; Black P; Weatherall M; Beasley R;
NPJ Prim Care Respir Med; 2015 Jan; 25():14099. PubMed ID: 25569185
[TBL] [Abstract][Full Text] [Related]
33. Why small particle fixed dose triple therapy? An excursus from COPD pathology to pharmacological treatment evolution.
Braido F; Corsico AG; Paleari D; Piraino A; Cavalieri L; Scichilone N
Ther Adv Respir Dis; 2022; 16():17534666211066063. PubMed ID: 35044875
[TBL] [Abstract][Full Text] [Related]
34. Drug interaction and chronic obstructive respiratory disorders.
Rogliani P; Ritondo BL; Zerillo B; Matera MG; Calzetta L
Curr Res Pharmacol Drug Discov; 2021; 2():100009. PubMed ID: 34909645
[TBL] [Abstract][Full Text] [Related]
35. Effects of (a Combination of) the Beta
Maarsingh H; Oldenburger A; Han B; Zuidhof AB; Elzinga CRS; Timens W; Meurs H; Sopi RB; Schmidt M
Cells; 2021 May; 10(5):. PubMed ID: 34069899
[TBL] [Abstract][Full Text] [Related]
36. Functional respiratory imaging assessment of glycopyrrolate and formoterol fumarate metered dose inhalers formulated using co-suspension delivery technology in patients with COPD.
De Backer W; De Backer J; Verlinden I; Leemans G; Van Holsbeke C; Mignot B; Jenkins M; Griffis D; Ivanov S; Fitzpatrick J; St Rose E; Martin UJ; Reisner C
Ther Adv Respir Dis; 2020; 14():1753466620916990. PubMed ID: 32380894
[TBL] [Abstract][Full Text] [Related]
37. Systematic review and network meta-analysis of the efficacy and safety of glycopyrrolate/formoterol fumarate metered dose inhaler in comparison with other long-acting muscarinic antagonist/long-acting β
Siddiqui MK; Shukla P; Jenkins M; Ouwens M; Guranlioglu D; Darken P; Biswas M
Ther Adv Respir Dis; 2019; 13():1753466619894502. PubMed ID: 31868101
[TBL] [Abstract][Full Text] [Related]
38. Optimizing the Development Strategy of Combination Therapy in Respiratory Medicine: From Isolated Airways to Patients.
Calzetta L; Matera MG; Cazzola M; Rogliani P
Adv Ther; 2019 Dec; 36(12):3291-3298. PubMed ID: 31654332
[TBL] [Abstract][Full Text] [Related]
39. Pharmacological treatment and current controversies in COPD.
Cazzola M; Rogliani P; Stolz D; Matera MG
F1000Res; 2019; 8():. PubMed ID: 31508197
[TBL] [Abstract][Full Text] [Related]
40. The once-daily fixed-dose combination of olodaterol and tiotropium in the management of COPD: current evidence and future prospects.
Derom E; Brusselle GG; Joos GF
Ther Adv Respir Dis; 2019; 13():1753466619843426. PubMed ID: 31002020
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
